Compounds > loxiglumide
Page last updated: 2024-08-24

loxiglumide and Pancreatic Neoplasms

loxiglumide has been researched along with Pancreatic Neoplasms in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's10 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fukumoto, M; Hayashi, H; Imamura, M; Kawabata, K; Manabe, T; Masai, Y; Morimoto, H; Nio, Y; Tsubono, M1
Baba, N; Hayashi, H; Hosokawa, Y; Kawabata, K; Manabe, T; Masai, Y; Morimoto, H; Nio, Y; Tseng, CC; Tsubono, M1
Miyazaki, N; Saito, Y; Tomioka, M; Yamamoto, M2
Hanada, K; Hirata, M; Itoh, M; Kajiyama, G; Ooishi, H; Tsuchida, A1
Di Prima, F; Militello, C; Pedrazzoli, S; Sperti, C1
Nio, Y; Tamura, K1
Funakoshi, A; Kono, A; Shimazoe, T1
Funakoshi, A; Kono, A1
Bastié, MJ; Pradayrol, L; Scemama, JL; Seva, C; Vaysse, N1

Reviews

1 review(s) available for loxiglumide and Pancreatic Neoplasms

ArticleYear
[Newly-developing therapies of pancreatic cancer--immunotherapy, gene therapy, differentiation therapy, endocrine therapy and others].
    Nihon Geka Gakkai zasshi, 1997, Volume: 98, Issue:7

    Topics: Animals; Benzodiazepinones; Deuterium Oxide; Devazepide; Genetic Therapy; Humans; Immunotherapy; Pancreatic Neoplasms; Proglumide; Quinolones; Receptors, Cholecystokinin

1997

Trials

1 trial(s) available for loxiglumide and Pancreatic Neoplasms

ArticleYear
Clinical evaluation and safety of loxiglumide (CCK-A receptor antagonist) in nonresectable pancreatic cancer patients. Italian Pancreatic Cancer Study Group.
    Pancreas, 1997, Volume: 14, Issue:3

    Topics: Double-Blind Method; Female; Hormone Antagonists; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Proglumide; Prospective Studies; Receptor, Cholecystokinin A; Receptors, Cholecystokinin; Safety; Survival Analysis

1997

Other Studies

8 other study(ies) available for loxiglumide and Pancreatic Neoplasms

ArticleYear
Loxiglumide (CR1505), a cholecystokinin antagonist, specifically inhibits the growth of human pancreatic cancer lines xenografted into nude mice.
    Cancer, 1993, Dec-15, Volume: 72, Issue:12

    Topics: Animals; Cell Division; Chloroquine; Cholecystokinin; DNA; Esters; Gabexate; Guanidines; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Organ Culture Techniques; Pancreatic Neoplasms; Proglumide; Sincalide; Transplantation, Heterologous

1993
Inhibitory effects of a cholecystokinin antagonist, loxiglumide (CR-1505), on the growth of freshly separated and xenografted human pancreatic cancer.
    Journal of surgical oncology, 1993, Volume: 53, Issue:1

    Topics: Animals; Carcinoma, Intraductal, Noninfiltrating; Cholecystokinin; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Proglumide; RNA, Neoplasm; Transplantation, Heterologous; Tumor Cells, Cultured

1993
[Effect of combined use of CR1505 with UFT for the tumor growth of the subcutaneously transplanted pancreatic cancer in the Syrian golden hamsters].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1993, Volume: 90, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cholecystokinin; Cricetinae; Mesocricetus; Neoplasm Transplantation; Nitrosamines; Pancreatic Neoplasms; Proglumide; Tegafur; Uracil

1993
Cholecystokinin receptor antagonist, loxiglumide, inhibits invasiveness of human pancreatic cancer cell lines.
    FEBS letters, 1996, Apr-01, Volume: 383, Issue:3

    Topics: Blotting, Western; Cell Line; Collagenases; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Gelatin; Hormone Antagonists; Humans; Kinetics; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Pancreatic Neoplasms; Proglumide; Sincalide; Tumor Cells, Cultured

1996
[Effects of UFT and loxiglumide (CR1505) on liver metastasis of human pancreatic cancer cell line, KP-1 N in nude mice].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cholecystokinin; Humans; Liver Neoplasms; Mice; Mice, Nude; Pancreatic Neoplasms; Proglumide; Tegafur; Tumor Cells, Cultured; Uracil

1992
[Effect of combined use of CR 1505 with UFT on tumor growth of transplanted pancreatic cancer in the Syrian golden hamster: preliminary report].
    Nihon Geka Gakkai zasshi, 1992, Volume: 93, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cholecystokinin; Cricetinae; Drug Synergism; Mesocricetus; Neoplasm Transplantation; Pancreatic Neoplasms; Proglumide; Tegafur; Uracil

1992
Growth inhibition of human pancreatic cancer cells by cholecystokinin receptor antagonist in tissue culture and in nude mice.
    Gastroenterologia Japonica, 1992, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Animals; Ceruletide; Cholecystokinin; Humans; In Vitro Techniques; Liver Neoplasms; Mice; Mice, Nude; Pancreatic Neoplasms; Proglumide; Tumor Cells, Cultured

1992
Lorglumide and loxiglumide inhibit gastrin-stimulated DNA synthesis in a rat tumoral acinar pancreatic cell line (AR42J).
    Cancer research, 1990, Sep-15, Volume: 50, Issue:18

    Topics: Animals; DNA, Neoplasm; Gastrins; Glutamine; Ornithine Decarboxylase; Pancreatic Neoplasms; Proglumide; Rats; Receptors, Cholecystokinin; Thymidine; Tumor Cells, Cultured

1990